drugset / Trial / NCT07594145
Precision T1D Platform - New Therapies for Cardio-Renal Complications
Phase 2
Not yet recruiting
57 enrolled
Oregon Health and Science University
Breakthrough T1D · collabUniversity of Michigan · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Breakthrough T1D has awarded support for a joint University of Michigan-Oregon Health \& Science University Center of Excellence (CoE) to address cardio-renal complications in T1D. The overarching hypothesis of the CoE is that individuals with T1D have unique endophenotypes determining their progression towards cardio-renal end organ damage. Defining the underlying molecular programs in T1D endophenotypes provides the rationale for testing existing or new drug candidates in mechanistic trials targeting T1D cardio-renal complications by matching endophenotypes to targeted therapies.
Timeline
- Start
- 2026-09-01
- Primary completion
- 2029-12-31
- Completion
- 2031-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Finerenone | Small molecule | 20 mg | Oral |
| Subject | Sotagliflozin | Small molecule | 200 mg | — |